Medarex Gets Milestone Payment

Medarex, Inc. announced that it has received a milestone payment of an undisclosed amount from its licensing partner, Centocor, Inc. Medarex received the payment for the submission of a Marketing Authorization Application to the European Medicines Agency requesting approval of golimumab, CNTO 148, for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
RTTNews